KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Depreciation & Amortization (CF): 2018-2025

Historic Depreciation & Amortization (CF) for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $52.0 million.

  • Moderna's Depreciation & Amortization (CF) changed negligibly% to $52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.0 million, marking a year-over-year decrease of 37.16%. This contributed to the annual value of $189.0 million for FY2024, which is 69.57% down from last year.
  • Moderna's Depreciation & Amortization (CF) amounted to $52.0 million in Q3 2025, which was down 8.77% from $57.0 million recorded in Q2 2025.
  • Moderna's 5-year Depreciation & Amortization (CF) high stood at $249.0 million for Q3 2023, and its period low was $15.0 million during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $57.0 million (2025), whereas its average is $87.1 million.
  • As far as peak fluctuations go, Moderna's Depreciation & Amortization (CF) soared by 1,014.29% in 2021, and later crashed by 79.12% in 2024.
  • Over the past 5 years, Moderna's Depreciation & Amortization (CF) (Quarterly) stood at $78.0 million in 2021, then grew by 2.56% to $80.0 million in 2022, then spiked by 152.50% to $202.0 million in 2023, then slumped by 70.30% to $60.0 million in 2024, then remained steady at $52.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $52.0 million in Q3 2025, compared to $57.0 million in Q2 2025 and $39.0 million in Q1 2025.